Tag Archives: fail
#437608 Video Friday: Agility Robotics Raises ...
Video Friday is your weekly selection of awesome robotics videos, collected by your Automaton bloggers. We’ll also be posting a weekly calendar of upcoming robotics events for the next few months; here’s what we have so far (send us your events!):
IROS 2020 – October 25-29, 2020 – [Online]
ROS World 2020 – November 12, 2020 – [Online]
CYBATHLON 2020 – November 13-14, 2020 – [Online]
ICSR 2020 – November 14-16, 2020 – Golden, Colo., USA
Let us know if you have suggestions for next week, and enjoy today’s videos.
Digit is now in full commercial production and we’re excited to announce a $20M funding rounding round co-led by DCVC and Playground Global!
Digits for everyone!
[ Agility Robotics ]
A flexible rover that has both ability to travel long distances and rappel down hard-to-reach areas of scientific interest has undergone a field test in the Mojave Desert in California to showcase its versatility. Composed of two Axel robots, DuAxel is designed to explore crater walls, pits, scarps, vents and other extreme terrain on the moon, Mars and beyond.
This technology demonstration developed at NASA’s Jet Propulsion Laboratory in Southern California showcases the robot’s ability to split in two and send one of its halves — a two-wheeled Axle robot — over an otherwise inaccessible slope, using a tether as support and to supply power.
The rappelling Axel can then autonomously seek out areas to study, safely overcome slopes and rocky obstacles, and then return to dock with its other half before driving to another destination. Although the rover doesn’t yet have a mission, key technologies are being developed that might, one day, help us explore the rocky planets and moons throughout the solar system.
[ JPL ]
A rectangular robot as tiny as a few human hairs can travel throughout a colon by doing back flips, Purdue University engineers have demonstrated in live animal models. Why the back flips? Because the goal is to use these robots to transport drugs in humans, whose colons and other organs have rough terrain. Side flips work, too. Why a back-flipping robot to transport drugs? Getting a drug directly to its target site could remove side effects, such as hair loss or stomach bleeding, that the drug may otherwise cause by interacting with other organs along the way.
[ Purdue ]
This video shows the latest results in the whole-body locomotion control of the humanoid robot iCub achieved by the Dynamic Interaction Control line at IIT-Istituto Italiano di Tecnologia in Genova (Italy). In particular, the iCub now keeps the balance while walking and receiving pushes from an external user. The implemented control algorithms also ensure the robot to remain compliant during locomotion and human-robot interaction, a fundamental property to lower the possibility to harm humans that share the robot surrounding environment.
This is super impressive, considering that iCub was only able to crawl and was still tethered not too long ago. Also, it seems to be blinking properly now, so it doesn’t look like it’s always sleepy.
[ IIT ]
This video shows a set of new tests we performed on Bolt. We conducted tests on 5 different scenarios, 1) walking forward/backward 2) uneven surface 3) soft surface 4) push recovery 5) slippage recovery. Thanks to our feedback control based on Model Predictive Control, the robot can perform walking in the presence of all these uncertainties. We will open-source all the codes in a near future.
[ ODRI ]
The title of this video is “Can you throw your robot into a lake?” The title of this video should be, “Can you throw your robot into a lake and drive it out again?”
[ Norlab ]
AeroVironment Successfully Completes Sunglider Solar HAPS Stratospheric Test Flight, Surpassing 60,000 Feet Altitude and Demonstrating Broadband Mobile Connectivity.
[ AeroVironment ]
We present CoVR, a novel robotic interface providing strong kinesthetic feedback (100 N) in a room-scale VR arena. It consists of a physical column mounted on a 2D Cartesian ceiling robot (XY displacements) with the capacity of (1) resisting to body-scaled users actions such as pushing or leaning; (2) acting on the users by pulling or transporting them as well as (3) carrying multiple potentially heavy objects (up to 80kg) that users can freely manipulate or make interact with each other.
[ DeepAI ]
In a new video, personnel from Swiss energy supply company Kraftwerke Oberhasli AG (KWO) explain how they were able to keep employees out of harm’s way by using Flyability’s Elios 2 to collect visual data while building a new dam.
[ Flyability ]
Enjoy our Ascento robot fail compilation! With every failure we experience, we learn more and we can improve our robot for its next iteration, which will come soon… Stay tuned for more!
FYI posting a robot fails video will pretty much guarantee you a spot in Video Friday!
[ Ascento ]
Humans are remarkably good at using chopsticks. The Guinness World Record witnessed a person using chopsticks to pick up 65 M&Ms in just a minute. We aim to collect demonstrations from humans and to teach robot to use chopsticks.
[ UW Personal Robotics Lab ]
A surprising amount of personality from these Yaskawa assembly robots.
[ Yaskawa ]
This paper presents the system design, modeling, and control of the Aerial Robotic Chain Manipulator. This new robot design offers the potential to exert strong forces and moments to the environment, carry and lift significant payloads, and simultaneously navigate through narrow corridors. The presented experimental studies include a valve rotation task, a pick-and-release task, and the verification of load oscillation suppression to demonstrate the stability and performance of the system.
[ ARL ]
Whether animals or plants, whether in the water, on land or in the air, nature provides the model for many technical innovations and inventions. This is summed up in the term bionics, which is a combination of the words ‘biology‘ and ‘electronics’. At Festo, learning from nature has a long history, as our Bionic Learning Network is based on using nature as the source for future technologies like robots, assistance systems or drive solutions.
[ Festo ]
Dogs! Selfies! Thousands of LEGO bricks! This video has it all.
[ LEGO ]
An IROS workshop talk on “Cassie and Mini Cheetah Autonomy” by Maani Ghaffari and Jessy Grizzle from the University of Michigan.
[ Michigan Robotics ]
David Schaefer’s Cozmo robots are back with this mind-blowing dance-off!
What you just saw represents hundreds of hours of work, David tells us: “I wrote over 10,000 lines of code to create the dance performance as I had to translate the beats per minute of the song into motor rotations in order to get the right precision needed to make the moves look sharp. The most challenging move was the SpongeBob SquareDance as any misstep would send the Cozmos crashing into each other. LOL! Fortunately for me, Cozmo robots are pretty resilient.”
[ Life with Cozmo ]
Thanks David!
This week’s GRASP on Robotics seminar is by Sangbae Kim from MIT, on “Robots with Physical Intelligence.”
While industrial robots are effective in repetitive, precise kinematic tasks in factories, the design and control of these robots are not suited for physically interactive performance that humans do easily. These tasks require ‘physical intelligence’ through complex dynamic interactions with environments whereas conventional robots are designed primarily for position control. In order to develop a robot with ‘physical intelligence’, we first need a new type of machines that allow dynamic interactions. This talk will discuss how the new design paradigm allows dynamic interactive tasks. As an embodiment of such a robot design paradigm, the latest version of the MIT Cheetah robots and force-feedback teleoperation arms will be presented.
[ GRASP ]
This week’s CMU Ri Seminar is by Kevin Lynch from Northwestern, on “Robotics and Biosystems.”
Research at the Center for Robotics and Biosystems at Northwestern University encompasses bio-inspiration, neuromechanics, human-machine systems, and swarm robotics, among other topics. In this talk I will give an overview of some of our recent work on in-hand manipulation, robot locomotion on yielding ground, and human-robot systems.
[ CMU RI ] Continue reading
#437261 How AI Will Make Drug Discovery ...
If you had to guess how long it takes for a drug to go from an idea to your pharmacy, what would you guess? Three years? Five years? How about the cost? $30 million? $100 million?
Well, here’s the sobering truth: 90 percent of all drug possibilities fail. The few that do succeed take an average of 10 years to reach the market and cost anywhere from $2.5 billion to $12 billion to get there.
But what if we could generate novel molecules to target any disease, overnight, ready for clinical trials? Imagine leveraging machine learning to accomplish with 50 people what the pharmaceutical industry can barely do with an army of 5,000.
Welcome to the future of AI and low-cost, ultra-fast, and personalized drug discovery. Let’s dive in.
GANs & Drugs
Around 2012, computer scientist-turned-biophysicist Alex Zhavoronkov started to notice that artificial intelligence was getting increasingly good at image, voice, and text recognition. He knew that all three tasks shared a critical commonality. In each, massive datasets were available, making it easy to train up an AI.
But similar datasets were present in pharmacology. So, back in 2014, Zhavoronkov started wondering if he could use these datasets and AI to significantly speed up the drug discovery process. He’d heard about a new technique in artificial intelligence known as generative adversarial networks (or GANs). By pitting two neural nets against one another (adversarial), the system can start with minimal instructions and produce novel outcomes (generative). At the time, researchers had been using GANs to do things like design new objects or create one-of-a-kind, fake human faces, but Zhavoronkov wanted to apply them to pharmacology.
He figured GANs would allow researchers to verbally describe drug attributes: “The compound should inhibit protein X at concentration Y with minimal side effects in humans,” and then the AI could construct the molecule from scratch. To turn his idea into reality, Zhavoronkov set up Insilico Medicine on the campus of Johns Hopkins University in Baltimore, Maryland, and rolled up his sleeves.
Instead of beginning their process in some exotic locale, Insilico’s “drug discovery engine” sifts millions of data samples to determine the signature biological characteristics of specific diseases. The engine then identifies the most promising treatment targets and—using GANs—generates molecules (that is, baby drugs) perfectly suited for them. “The result is an explosion in potential drug targets and a much more efficient testing process,” says Zhavoronkov. “AI allows us to do with fifty people what a typical drug company does with five thousand.”
The results have turned what was once a decade-long war into a month-long skirmish.
In late 2018, for example, Insilico was generating novel molecules in fewer than 46 days, and this included not just the initial discovery, but also the synthesis of the drug and its experimental validation in computer simulations.
Right now, they’re using the system to hunt down new drugs for cancer, aging, fibrosis, Parkinson’s, Alzheimer’s, ALS, diabetes, and many others. The first drug to result from this work, a treatment for hair loss, is slated to start Phase I trials by the end of 2020.
They’re also in the early stages of using AI to predict the outcomes of clinical trials in advance of the trial. If successful, this technique will enable researchers to strip a bundle of time and money out of the traditional testing process.
Protein Folding
Beyond inventing new drugs, AI is also being used by other scientists to identify new drug targets—that is, the place to which a drug binds in the body and another key part of the drug discovery process.
Between 1980 and 2006, despite an annual investment of $30 billion, researchers only managed to find about five new drug targets a year. The trouble is complexity. Most potential drug targets are proteins, and a protein’s structure—meaning the way a 2D sequence of amino acids folds into a 3D protein—determines its function.
But a protein with merely a hundred amino acids (a rather small protein) can produce a googol-cubed worth of potential shapes—that’s a one followed by three hundred zeroes. This is also why protein-folding has long been considered an intractably hard problem for even the most powerful of supercomputers.
Back in 1994, to monitor supercomputers’ progress in protein-folding, a biannual competition was created. Until 2018, success was fairly rare. But then the creators of DeepMind turned their neural networks loose on the problem. They created an AI that mines enormous datasets to determine the most likely distance between a protein’s base pairs and the angles of their chemical bonds—aka, the basics of protein-folding. They called it AlphaFold.
On its first foray into the competition, contestant AIs were given 43 protein-folding problems to solve. AlphaFold got 25 right. The second-place team managed a meager three. By predicting the elusive ways in which various proteins fold on the basis of their amino acid sequences, AlphaFold may soon have a tremendous impact in aiding drug discovery and fighting some of today’s most intractable diseases.
Drug Delivery
Another theater of war for improved drugs is the realm of drug delivery. Even here, converging exponential technologies are paving the way for massive implications in both human health and industry shifts.
One key contender is CRISPR, the fast-advancing gene-editing technology that stands to revolutionize synthetic biology and treatment of genetically linked diseases. And researchers have now demonstrated how this tool can be applied to create materials that shape-shift on command. Think: materials that dissolve instantaneously when faced with a programmed stimulus, releasing a specified drug at a highly targeted location.
Yet another potential boon for targeted drug delivery is nanotechnology, whereby medical nanorobots have now been used to fight incidences of cancer. In a recent review of medical micro- and nanorobotics, lead authors (from the University of Texas at Austin and University of California, San Diego) found numerous successful tests of in vivo operation of medical micro- and nanorobots.
Drugs From the Future
Covid-19 is uniting the global scientific community with its urgency, prompting scientists to cast aside nation-specific territorialism, research secrecy, and academic publishing politics in favor of expedited therapeutic and vaccine development efforts. And in the wake of rapid acceleration across healthcare technologies, Big Pharma is an area worth watching right now, no matter your industry. Converging technologies will soon enable extraordinary strides in longevity and disease prevention, with companies like Insilico leading the charge.
Riding the convergence of massive datasets, skyrocketing computational power, quantum computing, cognitive surplus capabilities, and remarkable innovations in AI, we are not far from a world in which personalized drugs, delivered directly to specified targets, will graduate from science fiction to the standard of care.
Rejuvenational biotechnology will be commercially available sooner than you think. When I asked Alex for his own projection, he set the timeline at “maybe 20 years—that’s a reasonable horizon for tangible rejuvenational biotechnology.”
How might you use an extra 20 or more healthy years in your life? What impact would you be able to make?
Join Me
(1) A360 Executive Mastermind: If you’re an exponentially and abundance-minded entrepreneur who would like coaching directly from me, consider joining my Abundance 360 Mastermind, a highly selective community of 360 CEOs and entrepreneurs who I coach for 3 days every January in Beverly Hills, Ca. Through A360, I provide my members with context and clarity about how converging exponential technologies will transform every industry. I’m committed to running A360 for the course of an ongoing 25-year journey as a “countdown to the Singularity.”
If you’d like to learn more and consider joining our 2021 membership, apply here.
(2) Abundance-Digital Online Community: I’ve also created a Digital/Online community of bold, abundance-minded entrepreneurs called Abundance-Digital. Abundance-Digital is Singularity University’s ‘onramp’ for exponential entrepreneurs—those who want to get involved and play at a higher level. Click here to learn more.
(Both A360 and Abundance-Digital are part of Singularity University—your participation opens you to a global community.)
This article originally appeared on diamandis.com. Read the original article here.
Image Credit: andreas160578 from Pixabay Continue reading